Stoke Therapeutics, Inc. - Common Stock (STOK)
CUSIP: 86150R107
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 57,529,259
- Total 13F shares
- 65,548,147
- Share change
- +2,162,250
- Total reported value
- $743,993,162
- Price per share
- $11.35
- Number of holders
- 133
- Value change
- +$30,166,679
- Number of buys
- 73
- Number of sells
- 49
Quarterly Holders Quick Answers
What is CUSIP 86150R107?
CUSIP 86150R107 identifies STOK - Stoke Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 86150R107:
Top shareholders of STOK - Stoke Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13D/G
13F
|
Company |
8%
|
4,375,931
|
$52,554,931 | $0 | 30 Jun 2025 | |
| RTW INVESTMENTS, LP |
13D/G
13F
|
Company |
10%
|
5,310,033
|
$50,498,414 | $0 | 31 Dec 2024 | |
| Skorpios Trust |
13F
3/4/5
|
Company · 10%+ Owner |
6.8%
from 3/4/5
|
6,906,181
|
$45,926,104 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
10%
|
5,862,436
|
$38,985,198 | — | 31 Mar 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
9.2%
|
5,291,929
|
$35,191,328 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13D/G
13F
|
Company |
6.5%
|
3,426,739
|
$32,588,288 | $0 | 31 Dec 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
8.1%
|
4,633,838
|
$30,815,023 | — | 31 Mar 2025 | |
| BlackRock Portfolio Management LLC |
13D/G
|
— |
4.7%
|
2,550,341
|
$28,946,115 | -$2,192,358 | 30 Jun 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
5.5%
|
3,173,258
|
$21,102,166 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.8%
|
2,784,202
|
$18,514,945 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
4.4%
|
2,541,937
|
$16,903,882 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
3.9%
|
2,247,347
|
$14,944,858 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
3.7%
|
2,131,783
|
$14,176,357 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.9%
|
1,662,039
|
$11,052,560 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
1,575,283
|
$10,475,632 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
1.7%
|
959,603
|
$6,381,360 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
901,986
|
$5,999,613 | — | 31 Mar 2025 | |
| Checkpoint Capital L.P. |
13F
|
Company |
1.3%
|
730,717
|
$4,859,268 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.2%
|
693,988
|
$4,615,020 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.2%
|
664,735
|
$4,423,135 | — | 31 Mar 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
1.1%
|
660,430
|
$4,391,860 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.93%
|
532,884
|
$3,543,678 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.87%
|
500,000
|
$3,325,000 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.77%
|
443,998
|
$2,952,587 | — | 31 Mar 2025 | |
| Erste Asset Management GmbH |
13F
|
Company |
0.69%
|
396,000
|
$2,670,360 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.62%
|
357,248
|
$2,375,699 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.6%
|
346,664
|
$2,305,315 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.58%
|
335,360
|
$2,230,143 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.54%
|
310,307
|
$2,063,542 | — | 31 Mar 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.52%
|
300,000
|
$1,995,000 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.44%
|
254,161
|
$1,690,171 | — | 31 Mar 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.37%
|
210,005
|
$1,396,533 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.31%
|
178,300
|
$1,185,695 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.3%
|
171,831
|
$1,142,676 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.24%
|
135,960
|
$904,134 | — | 31 Mar 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.22%
|
125,861
|
$836,976 | — | 31 Mar 2025 | |
| Stephen J. Tulipano |
3/4/5
|
Former CFO |
—
mixed-class rows
|
120,746
mixed-class rows
|
$757,722 | — | 27 Mar 2024 | |
| Nuveen, LLC |
13F
|
Company |
0.19%
|
108,087
|
$718,779 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.19%
|
107,562
|
$715,287 | — | 31 Mar 2025 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
0.18%
|
105,817
|
$703,683 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.18%
|
103,779
|
$690,130 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.17%
|
95,120
|
$632,548 | — | 31 Mar 2025 | |
| Huw M. Nash |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
86,000
mixed-class rows
|
$631,200 | — | 02 Jul 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
89,985
|
$598,400 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.15%
|
86,140
|
$572,831 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.14%
|
82,802
|
$550,634 | — | 31 Mar 2025 | |
| Fort Point Capital Partners LLC |
13F
|
Company |
0.13%
|
75,429
|
$501,603 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.13%
|
74,620
|
$496,223 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.12%
|
68,361
|
$454,602 | — | 31 Mar 2025 | |
| Swiss National Bank |
13F
|
Company |
0.12%
|
67,300
|
$447,545 | — | 31 Mar 2025 |
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock (STOK) as of Q2 2025
As of 30 Jun 2025,
Stoke Therapeutics, Inc. - Common Stock (STOK) was held by
133 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,548,147 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., Lynx1 Capital Management LP, RTW INVESTMENTS, LP, BAKER BROS. ADVISORS LP, Redmile Group, LLC, MORGAN STANLEY, Skorpios Trust, TORONTO DOMINION BANK, and VANGUARD GROUP INC.
This page lists
133
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
124
Q2 2025 holders
133
Holder diff
9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.